NVCRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
NovoCure Ltd
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 23, 2026
$14.89+0.82 (+5.83%)
Close on Oct 19, 2026
- Market cap
- $1.73B
- P/E (TTM)
- –
- Dividend yield
- –
NovoCure statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Surgical & Medical Instruments & Apparatus companies for comparison
Valuation
| Measure | NovoCure | Industry median |
|---|---|---|
| Market Cap | $1.73B | $229.23M |
| Enterprise Value | $1.64B | $194.73M |
| PS Ratio | 2.48 | 3.14 |
| PB Ratio | 5.13 | 3.19 |
| P/TBV Ratio | 5.13 | 4.69 |
Enterprise value
| Measure | NovoCure | Industry median |
|---|---|---|
| EV / Sales | 2.35 | 2.93 |
Income (trailing twelve months)
| Measure | NovoCure | Industry median |
|---|---|---|
| Revenue | $699.19M | $102.39M |
| Gross Profit | $532.27M | $60.36M |
| Operating Income | -$154.40M | -$4.31M |
| Pretax Income | -$152.69M | -$2.26M |
| Net Income | -$148.57M | -$6.57M |
| EBITDA | -$138.08M | -$1.98M |
| EPS (Diluted) | -$1.30 | -$0.07 |
Margins
| Measure | NovoCure | Industry median |
|---|---|---|
| Gross Margin | 76.1% | 55.1% |
| Operating Margin | -22.1% | -6.04% |
| Pretax Margin | -21.8% | -4.11% |
| Profit Margin | -21.2% | -10.5% |
| EBITDA Margin | -19.7% | -2.67% |
| FCF Margin | -3.64% | -0.30% |
Returns
| Measure | NovoCure | Industry median |
|---|---|---|
| Return on Equity (ROE) | -43.2% | -19.2% |
| Return on Assets (ROA) | -14.6% | -13.3% |
| Return on Invested Capital (ROIC) | -54.9% | -4.11% |
| Return on Capital Employed (ROCE) | -26.9% | -9.07% |
Growth
| Measure | NovoCure | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 11.0% | 8.85% |
| Revenue Growth (3Y CAGR) | 6.81% | 7.08% |
| Revenue Growth (5Y CAGR) | 5.80% | 11.8% |
Balance sheet
| Measure | NovoCure | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $93.70M | $37.33M |
| Net Cash (Debt) | $93.70M | $3.92M |
| Net Cash Per Share | $0.80 | $0.28 |
| Equity (Book Value) | $338.09M | $57.36M |
| Book Value Per Share | $2.90 | $2.81 |
| Tangible Book Value | $338.09M | $10.71M |
| Working Capital | $417.81M | $54.64M |
Financial position
| Measure | NovoCure | Industry median |
|---|---|---|
| Current Ratio | 2.89 | 2.50 |
| Quick Ratio | 0.87 | 1.54 |
Cash flow (trailing twelve months)
| Measure | NovoCure | Industry median |
|---|---|---|
| Operating Cash Flow | -$2.82M | -$653.46K |
| Capital Expenditures | -$22.62M | -$3.69M |
| Free Cash Flow | -$25.43M | -$835.02K |
| FCF Per Share | -$0.22 | -$0.02 |
Efficiency
| Measure | NovoCure | Industry median |
|---|---|---|
| Asset Turnover | 0.69 | 0.59 |
| Inventory Turnover | 4.05 | 2.21 |
| Revenue Per Employee | $435.63K | $322.75K |
| Profits Per Employee | -$92.56K | -$52.11K |
| Employee Count | 1,605 | 197 |
Dividends and yields
| Measure | NovoCure | Industry median |
|---|---|---|
| Earnings Yield | -8.57% | -6.92% |
| FCF Yield | -1.47% | -0.62% |
| Buyback Yield | -0.21% | 0.78% |
| Shareholder Yield | -0.21% | 0.84% |
Shares
| Measure | NovoCure | Industry median |
|---|---|---|
| Shares Outstanding | 116,446,000 | 44,856,700 |
| Shares Change (YoY) | 3.60% | 3.35% |
| Shares Change (QoQ) | 0.54% | 0.27% |
| Float | 112,921,000 | 36,934,400 |
| Shares Held by Insiders | 3.03% | 10.6% |
Taxes
| Measure | NovoCure | Industry median |
|---|---|---|
| Income Tax | -$4.12M | $1.52M |
Scores
| Measure | NovoCure | Industry median |
|---|---|---|
| Altman Z-Score | 0.72 | 1.95 |
| Piotroski F-Score | 4 | 5 |
| Beneish M-Score | -2.24 | -2.64 |
Calculated by StockData from NovoCure's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.